ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
Ryosuke Okamura, Shumei Kato, Suzanna Lee, Rebecca E Jimenez, Jason K Sicklick, Razelle Kurzrock
Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000438; DOI: 10.1136/jitc-2019-000438